351 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1900)
- Addiction (16)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (28)
- Blood Disorders (38)
- Bone & Muscle (10)
- Cancer
(726)
- Bladder Cancer (14)
- Brain Cancer (25)
- Breast Cancer (70)
- Gastrointestinal (16)
- Gynecologic Cancer (28)
- Head and Neck Cancer (4)
- Kidney Cancer (8)
- Leukemia (75)
- Liver Cancer (10)
- Lung Cancer (62)
- Lymphoma (45)
- Multiple Myeloma (30)
- Pancreatic Cancer (22)
- Prostate Cancer (36)
- Sarcoma (25)
- Skin Cancer (30)
- Solid Tumors (42)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (37)
- Critical Illness (1)
- Dental (2)
- Developmental Disorders (2)
- Diabetes (22)
- Ear, Nose and Throat (11)
- Endocrine & Metabolic Disease (13)
- Eye (8)
- Gastrointestinal and Digestive Diseases (22)
- Hair and Skin Disorders (2)
- Headaches (5)
- Healthy Volunteers (175)
- Heart Disease (128)
- Infectious Disease (48)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (48)
- Lung Disease (32)
- Meniere's Disease (1)
- Neurological Disorders (174)
- Nutrition (4)
- Obesity (9)
- Obstetrics & Gynecology (51)
- Pain Management (1)
- Pediatrics (104)
- Psychiatric Disorders (65)
- Rehabilitation (8)
- Stroke (7)
- Surgery (7)
- Transplant (51)
- Urology (4)
- Vascular Conditions (9)
Displaying 1 - 10 of 10
Condition: Liver Disease / Cirrhosis of the Liver
Investigator: Elizabeth Verna, MD
Status: Currently Recruiting
LCN Cohort Study is an observational study designed to identify risk factors and develop prediction models for risk of decompensation in adults with liver cirrhosis. LCN Cohort Study involves multiple institutions and an anticipated 1200 participants. Enrolled participants will have study visits every 6 months for a total of 3 years. Some of the visit…
Condition: Liver Disease / Cirrhosis of the Liver
Investigator: Elizabeth Verna, MD
Status: Closed
The purpose of this research study is to determine whether rosuvastatin is safe and can help people living with cirrhosis lead longer, healthier lives. The study drug, rosuvastatin, is investigational, meaning it has not yet been approved for market use for this disease condition by the United States Food and Drug Administration (FDA). Participants will…
Condition: Liver Disease / Cirrhosis of the Liver
Investigator: Elizabeth Verna, MD
Status: Closed
The Red-C 3131 Study is a phase 3 study is looking to see if a study medicine, rifaximin, can safely delay or prevent HE in adults who have been diagnosed with advanced liver cirrhosis. Adults who have been diagnosed with advanced liver cirrhosis, but who don't yet have HE may be eligible to join. About 466 patients will be enrolled across 200 sites.…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to test the good and bad effects of the combined treatment, using the drugs cetuximab and avelumab as well as avelumab by itself. Avelumab is a drug that works by triggering the immune system so it can try to attack the cancer again. Avelumab works in a similar way to cemiplimab, which is the usual drug for treatment of your…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for patients with recurrent or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). This study will test the safety of an experimental anti-cancer drug (MEDI4736). MEDI4736 is an antibody (a protein produced by the defense system of the body immune system) that has been made in the laboratory. MEDI4736 boosts the ability of your…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to determine the effectiveness and safety of study drug MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 and tremelimumab combination therapy in the treatment of patients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck who have progressed during or after treatment with…
Condition: Liver Disease / Cirrhosis of the Liver
Investigator: Julia Wattacheril, MD, MPH
Status: Closed
The purpose of this study is to evaluate whether cirrhosis occurs as a result of NASH. NASH is a disease that results when fat accumulates in the liver. GS-6624 is an experimental medication designed to help reverse the scarring process, and the purpose of this study is to see if GS-6624 can reverse the scarring in the liver and heal cirrhosis.
Condition: Liver Disease / Cirrhosis of the Liver
Investigator: Robert Brown, MD, MPH
Status: Closed
The purpose of this study is to evaluate the efficacy of the drug OCR-002 for the treatment of an acute hepatic encephalopathy episode in cirrhotic patients requiring hospitalization. Subjects who have been recently hospitalized will potentially receive OCR-002 via infusion on top of their standard care for 5 days. Patients will be assessed 24-hours after…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for adult subjects with head and neck cancer (oral cavity, oropharynx middle part of the throat, hypopharynx bottom part of the throat, or larynx part of throat between the base of the tongue and the windpipe) that has either returned after treatment (recurrent) or is newly diagnosed. If newly diagnosed, the cancer must be metastatic,…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with melanoma, non-small cell lung cancer (NSCLC), or squamous cell cancer of the head and neck (SCCHN) that has a protein called B7-H3 on the tumor cells or blood vessels in thetumor. The purpose of this study is to test the safety, tolerability, and most effective dose ofMGA271 in combination with ipilimumab (also called Yervoy…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE